Wright Medical (WMGI) reported overall preliminary 4Q17 revenue of US $217.6MM, +12.7% vs. 4Q16, and full-year 2017 revenue of $745.0MM, +7.9% vs. 2016—the maximum of its revenue range that was revised down in 3Q17.
Leadership attributes 4Q growth to strong performance in U.S. upper extremities, driven by the PERFORM Reversed glenoid launch and ongoing sales of the SIMPLICITI shoulder. PERFORM and BLUEPRINT 3D surgical planning software are expected to remain growth supporters in 2018. (Recall that WMGI acquired the developer of BLUEPRINT’s base technology at the end of 2017.)
Leadership noted a 4Q supply constraint issue relating to a third-party coating vendor, which was addressed but which impacted total ankle production in the quarter.
Final financial results and 2018 guidance will be announced on February 27, 2018.
Wright Medical (WMGI) reported overall preliminary 4Q17 revenue of US $217.6MM, +12.7% vs. 4Q16, and full-year 2017 revenue of $745.0MM, +7.9% vs. 2016—the maximum of its revenue range that was revised down in 3Q17.
Leadership attributes 4Q growth to strong performance in U.S. upper extremities, driven by the PERFORM Reversed glenoid launch...
Wright Medical (WMGI) reported overall preliminary 4Q17 revenue of US $217.6MM, +12.7% vs. 4Q16, and full-year 2017 revenue of $745.0MM, +7.9% vs. 2016—the maximum of its revenue range that was revised down in 3Q17.
Leadership attributes 4Q growth to strong performance in U.S. upper extremities, driven by the PERFORM Reversed glenoid launch and ongoing sales of the SIMPLICITI shoulder. PERFORM and BLUEPRINT 3D surgical planning software are expected to remain growth supporters in 2018. (Recall that WMGI acquired the developer of BLUEPRINT’s base technology at the end of 2017.)
Leadership noted a 4Q supply constraint issue relating to a third-party coating vendor, which was addressed but which impacted total ankle production in the quarter.
Final financial results and 2018 guidance will be announced on February 27, 2018.
Copy to clipboard 
